RECURSION PHARMACEUTICALS, INC. Lease, Cost
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Lease, Cost of $28.08 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. lease, cost for the quarter ending 2024-12-31 was $7.06M, a 175.75% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. lease, cost for the quarter ending 2024-09-30 was $5.82M, a 122.08% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. lease, cost for the quarter ending 2024-06-30 was $5.21M, a 103.48% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. lease, cost for the quarter ending 2024-03-31 was $3.05M, a 14.88% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. lease, cost for fiscal 2025 was $28.08M, a 32.79% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. lease, cost for fiscal 2024 was $21.14M, a 103.34% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. lease, cost for fiscal 2023 was $10.40M, a 17.33% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. lease, cost for fiscal 2022 was $8.86M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $28.08M 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $7.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.88M derived: sum of 2 quarters · filed 2026-02-25 | $18.09M derived: sum of 3 quarters · filed 2026-02-25 | $21.14M 10-K · filed 2026-02-25 |
| 2024-09-30 | $5.82M 10-Q · filed 2024-11-06 | $11.03M derived: sum of 2 quarters · filed 2024-11-06 | $14.08M 10-Q · filed 2024-11-06 | $16.64M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $5.21M 10-Q · filed 2024-08-08 | $8.26M 10-Q · filed 2024-08-08 | $10.82M derived: sum of 3 quarters · filed 2026-02-25 | $13.44M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $3.05M 10-Q · filed 2024-05-09 | $5.61M derived: sum of 2 quarters · filed 2026-02-25 | $8.23M derived: sum of 3 quarters · filed 2026-02-25 | $10.79M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.18M derived: sum of 2 quarters · filed 2026-02-25 | $7.74M derived: sum of 3 quarters · filed 2026-02-25 | $10.40M 10-K · filed 2026-02-25 |
| 2023-09-30 | $2.62M 10-Q · filed 2024-11-06 | $5.18M derived: sum of 2 quarters · filed 2024-11-06 | $7.84M 10-Q · filed 2024-11-06 | $10.13M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $2.56M 10-Q · filed 2024-08-08 | $5.22M 10-Q · filed 2024-08-08 | $7.50M derived: sum of 3 quarters · filed 2025-02-28 | $9.62M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $2.65M 10-Q · filed 2024-05-09 | $4.95M derived: sum of 2 quarters · filed 2025-02-28 | $7.06M derived: sum of 3 quarters · filed 2025-02-28 | $9.49M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $4.41M derived: sum of 2 quarters · filed 2025-02-28 | $6.83M derived: sum of 3 quarters · filed 2025-02-28 | $8.86M 10-K · filed 2025-02-28 |
| 2022-09-30 | $2.12M 10-Q · filed 2023-11-09 | $4.54M derived: sum of 2 quarters · filed 2023-11-09 | $6.57M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $2.42M 10-Q · filed 2023-08-08 | $4.45M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $2.03M 10-Q · filed 2023-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |